Two articles I found this evening, first being from Dr stamler discussing inclusion criteria for the 201 study which was in the neurology journal April 2024.
https://www.neurology.org/doi/10.1212/WNL.0000000000206405
Second is from Biomelbourne network, discussing the latest 202 study results.
https://biomelbourne.org/alterity-therapeutics-reports-positive-interim-data-from-ath434-202-phase-2-clinical-trial-in-multiple-system-atrophy/
I found it a good comparison and review of the 67 patients included into the 201 study, and the results of the 10 (7) patients of the 202 study.
Should definately be a good readout.
Article I found
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $2.401K | 800.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 77 | 110142186 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 150940914 | 62 |
View Market Depth
| Last trade - 10.20am 08/11/2024 (20 minute delay) ? |
| ATH (ASX) Chart |